ID: ALA5282733

Max Phase: Preclinical

Molecular Formula: C13H12N4

Molecular Weight: 224.27

Associated Items:

Representations

Canonical SMILES:  Cc1ccncc1-c1ccnc2c1cnn2C

Standard InChI:  InChI=1S/C13H12N4/c1-9-3-5-14-7-11(9)10-4-6-15-13-12(10)8-16-17(13)2/h3-8H,1-2H3

Standard InChI Key:  WXLMADXQJQWUIQ-UHFFFAOYSA-N

Associated Targets(Human)

Cytochrome P450 17A1 3627 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Cytochrome P450 1A2 26471 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 224.27Molecular Weight (Monoisotopic): 224.1062AlogP: 2.34#Rotatable Bonds: 1
Polar Surface Area: 43.60Molecular Species: NEUTRALHBA: 4HBD: 0
#RO5 Violations: 0HBA (Lipinski): 4HBD (Lipinski): 0#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 5.46CX LogP: 1.51CX LogD: 1.51
Aromatic Rings: 3Heavy Atoms: 17QED Weighted: 0.64Np Likeness Score: -1.30

References

1. Padmakar Darne C, Velaparthi U, Saulnier M, Frennesson D, Liu P, Huang A, Tokarski J, Fura A, Spires T, Newitt J, Spires VM, Obermeier MT, Elzinga PA, Gottardis MM, Jayaraman L, Vite GD, Balog A..  (2022)  The discovery of BMS-737 as a potent, CYP17 lyase-selective inhibitor for the treatment of castration-resistant prostate cancer.,  75  [PMID:36031020] [10.1016/j.bmcl.2022.128951]

Source